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Abstract
Background: Negative energy balance (NEB) is a common pathological foundation of ketosis and fatty liver. Liver
and fat tissue are the major organs of lipid metabolism and take part in modulating lipid oxidative capacity and
energy demands, which is also a key metabolic pathway that regulates NEB develop during perinatal period.
Fibroblast growth factor-21 (FGF-21) is a recently discovered protein hormone that plays an important and specific
regulating role in adipose lipid metabolism and liver gluconeogenesis for human and mouse. Our aim is to
investigate the variation and relationship between serum FGF-21 concentration and characteristic parameters
related to negative energy balance in different energy metabolism state.
Methods: In this research, five non-pregnant, non-lactating Holstein–Friesian dairy cows were randomly allocated
into two groups. The interventions were a controlled-energy diet (30 % of maintenance energy requirements) and
a moderate-energy diet (120 % of predicted energy requirements) that lasted for the duration of the experiment.
We measured biochemical parameters, serum FGF-21, leptin and insulin levels by commercial ELISA kits.
Results: The results showed that serum FGF-21 levels were significantly higher in both groups treated with a
controlled-energy diet, while FGF-21 levels in both groups treated with moderate-energy diet were low. FGF-21
levels exhibited a significant positive correlation with serum leptin levels, while an inverse relationship was found
between FGF-21 and blood glucose and β-hydroxybutyrate acid (BHBA) levels.
Conclusion: An increase in FGF-21 levels after a controlled-energy diet treatment may contribute to a positive metabolic
effect which could result in a new theoretical and practical basis for the preventive strategy of dairy cows with NEB.
Keywords: Serum FGF-21, Negative energy balance (NEB), Blood metabolites
Background
Negative energy balance (NEB) which is characterized by
gluconeogenesis and lipodystrophy is the pivotal point
and common pathological foundation of ketosis and
fatty liver. Liver and fat tissue are the major organs of
lipid metabolism and take part in modulating lipid oxi-
dative capacity and energy demands, which is also a key
metabolic pathway that regulates NEB development dur-
ing the perinatal period.
FGF-21 is a recently discovered protein hormone that
is found commonly in liver. FGF-21 plays an important
role in regulating adipose lipid metabolism and liver glu-
coneogenesis in humans and mice. Recent experimental
studies on mice have identified brown adipose tissue as
one of the key sources of FGF-21 when exposed to cold
conditions. It is mainly through Beta adrenaline and cyc-
lic adenosine monophosphate, which mediates norepin-
ephrine, and, finally an activated protein kinase to
mediate the process of FGF-21 gene transcription and
FGF-21 protein release [1, 2]. Experimental studies have
also identified that FGF-21 had a protective effect on
Diet Induced Obesity (DIO) mice, and an increase in
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energy expenditure and fat utilization were found in fur-
ther studies [3–5]. The expression of FGF-21 in the
murine liver is tightly regulated nutritionally. It is in-
creased by starvation and ketogenic state and decreased
by refeeding [6].
Human studies have shown that serum FGF-21 levels
were significantly higher in type 2 diabetes mellitus
(T2DM) patients relative to healthy controls, and this
suggests the possibility of direct positive metabolic ef-
fects of FGF-21 in humans [7]. Similarly, a positive rela-
tionship of serum FGF21 levels with liver lipid content
and Body Mass Index (BMI) [7] and an inverse relation-
ship of FGF-21 with serum adiponectin levels were
found in non-alcoholic fatty liver disease (NAFLD) pa-
tients. It may indicate that FGF-21 regulates mammals
in different energy states [8–10].
It was clear that the study of the new regulatory fac-
tor FGF-21 on human and mice yielded important re-
sults. However, the state of FGF-21 research in dairy
cows is just beginning. In contrast to these studies of
humans and other mammals, very little is known about
the regulation of FGF-21 in dairy cows. Recent experi-
mental studies have found that the content of FGF-21
increased rapidly postpartum and after that maintained
a lower level during the perinatal period [11, 12]. How-
ever, to our knowledge, no information about the
dynamic changes in FGF-21 levels after dietary inter-
vention in dairy cows is available. In view of the above
mentioned research status of FGF-21, there are some
key scientific problems that need clarification in the re-
lationship between FGF-21 and energy metabolism in
dairy cow:
(1)No information about how FGF-21 exerts a direct
influence on energy intake is available, although
variation in FGF-21 levels during the perinatal
period has been reported in dairy cows.
(2)There are still some theoretical issues to be resolved
on the effect that changes in energy intake have on
FGF-21 levels, and the effect that energy intake has
on FGF-21 levels.
To this end, our aim is to confirm a hypothesis that
FGF-21 might play the above-mentioned role in dairy
cows with NEB. Non-pregnant, non-lactating dairy cows
will be allocated randomly to our experiments to recre-
ate the energy deficit of perinatal period. By means of
biochemical technologies and clinical investigation, our
preliminary study will document the changes in FGF-21
concentration in the blood during energy insufficiency
and when being overfed, investigate the relationship be-
tween FGF-21 and some characteristic parameters re-
lated to energy metabolism in the blood, and reveal a
regulation for FGF-21 on energy balance in dairy cows.
Our work may provide a new theoretical and practical
basis for preventing NEB in dairy cows.
Methods
Ethics statement
The study was approved by the farm owner and all ex-
perimental animals were conducted according to the
International Guiding Principles for Biomedical Re-
search. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Heilong-
jiang Bayi Agricultural University.
Herd and cow selection
In northeastern China (MiShan, Heilongjiang, China),
commercial dairy herds from a large dairy farm were se-
lected to participate in the study. Five non-pregnant,
non-lactating Holstein–Friesian dairy cows (18 ± 4 months
of age) were allocated randomly based on specific condi-
tion needs of compliance with the study protocol. All
dairy cows were in good health.
Animal management
This study included ten Holstein cows, five dairy cows
were assigned randomly to two groups for the experi-
ment. Group A was treated with a moderate-energy diet
(120 % of predicted energy requirements) in the primary
stage of the experiment and then they were treated with
a controlled-energy diet (30 % of maintenance energy re-
quirements) afterwards. Group B was treated with a
Fig. 1 Design of trial
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controlled-energy diet (30 % of maintenance energy re-
quirements) first and then they were treated with a
moderate-energy diet (120 % of predicted energy re-
quirements) in the later stage. Each level of nutrition
was achieved by feeding appropriate amounts of a single
TMR (Total Mixed Rations). The TMR composition was
1.48 Mcal (Mega-calorie) net energy of lactation (NEL)
and 160 g of crude protein per kilogram of dry matter
(DM). Feeding duration for both the controlled-energy
and moderate-energy diets was 14 days; both groups
were given a moderate-energy diet (120 % of predicted
energy requirements) for 7 days before the change in
diet (Fig. 1).
Sample collection
Blood samples were collected from tail vein in early
morning before receving diet every day. After blood col-
lection, tubes without anticoagulant were placed in an
icebox and carried to the laboratory within 1 h of collec-
tion, after which they were placed at room temperature
for 30 min, centrifuged at 3000 g for 15 min, and then
stored at −20 °C until analysis.
Blood metabolites and hormones
Concentrations of FGF-21 were measured using a RD
Human Fibroblast Growth Factor-21 ELISA kit (R&D
Systems Inc. Minneapolis, MN, USA) on an automatic
biochemistry analyzer (JianCheng Biological Engineering
Research Institute, Nanjing, China). Glucagon (GC) was
measured with a RD Bovine Glucagon ELISA kit, growth
hormone (GH) was measured with a RD Bovine Growth
hormone ELISA kit, and insulin (INS) was measured
with a RD Bovine INS ELISA kit. All biochemical
parameters were analysed on a Huadong electronic
DG5033A microplate reader (Huadong, Nanjing, China).
Blood glucose (GLU), serum levels of triglycerides (TG)
and nonesterified fatty acid (NEFA) were measured dir-
ectly by using an automatic biochemistry analyzer.
Data collation and statistical analyses
Data in this study were collated and initially analyzed
using Excel 2013 (Microsoft Corp., Redmond, WA,
USA). Descriptive and graphical analyses were carried
out to verify the data. When appropriate, we used IBM
SPSS19.0 software (SPSS Inc. Chicago, IL) to analyze the
data. The results are expressed as means ± standard
error means (SEM). Changes in FGF-21 levels and hor-
monal parameters between two groups were evaluated
by an Independent Sample T-test. One-way ANOVA was
used to compare data from different time periods be-
tween the two groups, and multiple testing was cor-
rected using the LSD (Least Significant Difference)
method (Equal Variances Assumed) or the Dunnett T3
(Equal Variance not assumed). Pearson correlation tests
were used to calculate the relationships between FGF-21
levels and other parameters. Pearson’s correlation ana-
lysis and linear regression analysis were used to
analyze the correlation of BHBA and serum FGF-21.
In data testing, a P value <0.05 was considered statis-
tically significant.
Results
The body weight changes in dairy cow are shown in
Table 1. In this study, the body weight of dairy cows in
both group gained significantly when treated with a
moderate-energy diet and the loss of body weight were
noticed when dairy cows were treated with a controlled-
energy diet.
The relationship between serum FGF-21 and energy
intake level
Serum FGF-21 levels at different time point of two
groups are shown in Table 2. As expected, serum FGF-21
levels changed significantly after the variation in energy
intake. The variation tendency of FGF-21 is shown in
Fig. 2. It showed that Serum FGF-21 levels were closely
related to energy intake level.
Table 1 Variation in dairy cow weight changes between Group
A and Group B
Group Time point (Days)
1 14 21 35
A 337.80 ± 25.49 358.40 ± 24.39* 368.20 ± 22.74* 356.00 ± 22.33*
B 332.00 ± 29.43 318.60 ± 29.08* 328.60 ± 28.28 347.40 ± 25.10*
Unit of measurement: KG. Group A, treated with a moderate-energy diet in
primary stage and treated with a controlled-energy diet in later stage. Group
B, treated with a controlled-energy diet in primary stage and treated with a
moderate-energy diet in later stage. Values are means ± SEM. Statistical
significance is from one-way anova. *P < 0.05 vs. Baseline dairy cow weight
data in same group
Table 2 Variation in Serum FGF-21 changes between Group A and Group B
Group Time point (Days)
1 14 21 35
A 506.48 ± 48.01 442.12 ± 67.65* 405.39 ± 47.56* 594.24 ± 40.31*
B 493.72 ± 90.62 612.89 ± 80.70* 553.93 ± 121.38* 490.54 ± 62.19*
Group A, treated with a moderate-energy diet in primary stage and treated with a controlled-energy diet in later stage. Group B, treated with a controlled-energy
diet in primary stage and treated with a moderate-energy diet in later stage. Values are means ± SEM. Statistical significance is from one-way anova. *P < 0.05 vs.
Baseline FGF-21 data in same group
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Effect of energy intake on serum levels of FGF-21
We gathered clinical trial data for the two groups on
eight days over a 14-day period for dairy cows in two
groups that were fed two different energy-state diets.
Serum FGF-21 levels decreased significantly in Group A,
however, in dairy cows fed a moderate-energy diet in
Group B, serum FGF-21 levels increased significantly
(Table 3). There were no significant differences (P > 0.05)
in serum FGF-21 levels in the initial experiment phase
(1–4 days) between the two groups. As the experiment
went on, serum FGF-21 levels between two groups as-
sumed significant differences (P <0.05). Gradually lower
serum FGF-21 levels were found in Group A, which was
fed a moderate-energy diet. However, serum FGF-21
levels in Group B gradually peaked. We found that
serum FGF-21 levels significantly declined in the high
diet energy-state and increasing FGF-21 levels were
found in the low energy-state diet.
The relationship between metabolic characteristics and
FGF-21 levels under NEB
Experimental animals fed a controlled-energy diet were
in the initiation phase of NEB. This is to say that experi-
mental animals in Group A were experiencing NEB at
day 21–35 and Group B animals were in NEB at day 1–
14 after the experiment commenced. The biochemical
and hormonal characteristics of two groups at four tim-
ings are shown in Table 4 and Table 5. The relationship
between serum FGF-21 levels and metabolic characteris-
tics in NEB in different experimental phases of the two
groups are shown in Table 6. Serum FGF-21 levels were
showed a significant positive correlation with serum lep-
tin levels, while we obtained a negative correlation of
FGF-21 with blood glucose and BHBA levels. On the
contrary, FGF-21 levels were not significantly related to
serum glucagon, triglyceride, non-esterified fatty acid, or
insulin levels.
Discussion
Our experiment makes references to perinatal period
model reported by Schoenberg [11], and our research
group adequately improve the design of experiment to
study the relationship between serum FGF-21 concen-
tration and characteristic parameters related to energy
balance in different energy metabolism states. Our study
demonstrated that dairy cows that were under a
controlled-energy diet significantly increased their serum
FGF-21 levels, but for dairy cows that were under a
moderate-energy diet, serum FGF-21 levels decreased
significantly. FGF-21 levels of dairy cows feeding
controlled-energy diet was significantly higher than dairy
cows feeding moderate-energy diet. At the onset of the
experiments (1–4 days), serum FGF-21 levels showed no
significant change. Similarly, other experiments found
that short-term fasting (12–48 h) had no effect on serum
Fig. 2 Variation of Serum FGF-21 changes between Group A and Group B. Changes in FGF21 concentrations during the variation of energy intake
of control Group A (dash line with filled circles), and changes in FGF21 concentrations during the variation of energy intake for control Group B
(solid line with open circles). Statistical significance is based on a one-way anova: *P < 0.05 vs. baseline FGF-21 value in same group
Table 3 The effect of energy intake on Serum FGF-21
concentration over a 14-day period
Experiment days Group
A B
1 506.48 ± 48.01 493.72 ± 90.62
2 499.62 ± 58.79 475.33 ± 21.39
4 497.43 ± 86.13* 508.45 ± 94.74*
6 483.81 ± 54.40* 524.01 ± 49.61*
8 478.35 ± 111.16* 526.83 ± 94.43*
10 456.91 ± 44.47** 556.11 ± 83.56*
12 447.80 ± 54.94* 595.51 ± 74.81*
14 442.12 ± 67.65** 612.89 ± 80.70*
Group A, treated with a moderate-energy diet; Group B, treated with a
controlled-energy diet. Values are means ± SEM. Statistical significance is from
an Independent Sample T test. *P < 0.05 vs. Baseline FGF-21 data in
same group
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FGF-21 levels. However, an increase in acetobutyric acid
level induced a significant increase in ketone bodies, and
resulted in a 74 % increase in serum FGF-21 levels after
7 days of fasting [13]. Our study showed a significant
decrease in serum FGF-21 levels in dairy cows under a
moderate-energy diet. Collectively, this finding is in
agreement with previous studies that serum FGF-21
levels and FGF-21 gene expression in liver significantly
decreased when cows were over-fed [14, 15]. In animal
models, obesity and T2DM have decreased serum FGF-
21 levels and reduced FGF-21 gene expression [16] and,
therefore, proposed that obesity is an FGF21-resistant
state [10]. Dairy cows under a controlled-energy diet
showed a significant increase in serum FGF-21 levels,
which can be interpreted as a response to a low-energy
diet [17]. A moderate-energy diet led to hyperphagia
that was induced in dairy cows by the administration of
FGF-21; this is indicative of FGF21-induced effects as a
major regulator of feeding. Previous studies on changes
in gene expression in the hypothalamus of FGF21-dosed
DIO mice have shown that hyperphagia may occur via a
compensatory nutrient, sensing-mediated process [18].
This response is due to FGF21-induced increases in en-
ergy expenditure due to the elevation in mRNAs for
appetite-promoting hypothalamic neuropeptides, agouti-
related peptide (AGRP) and nerve peptide Y (NPY). In-
deed, these results indicate that FGF-21 exerts a direct
influence on energy intake and also showe FGF-21 as an
important endocrine and energy balance state regulator
of metabolic homeostasis in dairy cows.
Here we showed that the relationship between serum
FGF-21 levels and energy intake under conditions of
negative energy balance. Our results demonstrate that
serum FGF-21 levels increased significantly under NEB,
induced by low-energy intake. Similarly, FGF-21 levels
exhibited a long-term increase after parturition under
NEB that was induced by a restriction of feed during late
lactation. These results are consistent with our experi-
mental findings, which showed that a lack of energy was
the key factor that led to the increase in serum FGF-21
levels in early-lactation. This result also illustrates that
FGF-21 levels are closely related to the regulation of en-
ergy metabolism. Our correlation analysis showed that
FGF-21 levels had an inverse relationship with blood
glucose. On the contrary, FGF-21 levels were not signifi-
cantly related to insulin levels, which suggests that
changes in FGF-21 levels is independent of variation in
insulin levels. Previous experimental studies have
Table 4 Variation in Serum characteristic parameters changes in Group A
Parameters Time point (Days)
A1 A14 A21 A35
Glc (mmol/L) 4.10 ± 0.43 4.34 ± 0.31* 4.96 ± 0.52* 3.89 ± 0.31*
BHBA (μmol/L) 640.73 ± 68.52 698. 63 ± 82.14* 760.63 ± 76.40* 615.73 ± 88.76
TG (mmol/L) 0.07 ± 0.03 0.09 ± 0.05 0.11 ± 0.05 0.08 ± 0.03
NEFA (μmol/L) 318.27 ± 32.65 321.52 ± 43.31 352.32 ± 22.58 298.27 ± 58.31
GC (pg/mL) 545.87 ± 130.54 550.47 ± 96.20 553.87 ± 83.24 563.87 ± 143.84
INS (mIU/L) 10.13 ± 3.86 11.38 ± 3.97 15.36 ± 5.23* 10.09 ± 3.15
LP (μg/L) 304.38 ± 29.54 282.59 ± 39.96* 268.34 ± 28.22* 312.89 ± 39.96
GH(ng/mL) 5.68 ± 1.86 5.47 ± 1.44 5.40 ± 1.33 5.63 ± 1.20
Values are means ± SEM. Statistical significance is from one-way anova. *P < 0.05 vs. Baseline Serum characteristic parameters data in same group
Table 5 Variation in Serum characteristic parameters changes in Group A
Parameters Time point (Days)
B1 B14 B21 B35
Glc (mmol/L) 4.16 ± 0.82 3.85 ± 0.34* 4.11 ± 0.51 4.87 ± 1.22*
BHBA (μmol/L) 620.52 ± 76.51 601.39 ± 55.61* 631.75 ± 89.37* 813.46 ± 81.78*
TG (mmol/L) 0.06 ± 0.03 0.08 ± 0.02 0.10 ± 0.04 0.10 ± 0.02
NEFA (μmol/L) 351.28 ± 64.23 334.85 ± 43.54 345.44 ± 28.22* 368.56 ± 78.52
GC (pg/mL) 553.87 ± 134.66 586.93 ± 93.55 516.23 ± 83.22 563.62 ± 111.21
INS (mIU/L) 11.25 ± 3.44 11.24 ± 3.59 13.07 ± 3.38* 16.37 ± 4.16*
LP (μg/L) 310.83 ± 38.58 313.49 ± 66.13 289.64 ± 75.43* 274.46 ± 42.58*
GH(ng/mL) 5.51 ± 1.64 5.68 ± 1.42 5.47 ± 1.44 5.54 ± 1.37
Values are means ± SEM. Statistical significance is from one-way anova. *P < 0.05 vs. Baseline Serum characteristic parameters data in same group
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similarly shown that FGF-21 can stimulate the uptake of
non-insulin-dependent glucose [19] and that it has a
positive impact on insulin sensitivity [20].
Current experimental research has shown that FGF-21
is a significant metabolic regulator that is produced pri-
marily by the liver; it is necessary for normal activation
of hepatic lipid oxidation, removal of triglycerides, keto-
genesis induced by ketogenic diet, and adapting to fast-
ing [21]. Our study demonstrated that serum FGF-21
levels and energy intake are closely related in dairy cows,
and we also demonstrated the tendency of FGF-21 to
vary under two different energy-state diets. The clarifica-
tion of the molecular mechanism underlying the effects
that FGF-21 plays in dietary interventions in NEB and
its potential in the treatment of metabolic abnormalities
in dairy cows with metabolic syndrome require further
investigation.
Conclusions
In summary, serum FGF-21 exerts a direct influence on
energy intake levels, and serum FGF-21 significantly de-
clines under high-energy diets and vice versa. We found
that FGF-21 levels exhibited a significant positive correl-
ation with serum leptin levels, while we found an inverse
relationship between FGF-21 with blood glucose and
BHBA levels.
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